Sartorius Stedim Biotech

DIM

Equity

ISIN FR0013154002 / Valor 32518471

Euronext - Euronext Paris (2026-10-08)

EUR 208.00-4.94%

Sartorius Stedim Biotech
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sartorius Stedim Biotech is a prominent global player in the biopharmaceutical industry, specializing in the development and manufacturing of biotech medications and vaccines. With a workforce of approximately 9,900 employees and operations in over 30 countries, the company provides a comprehensive range of products and technologies that support all critical stages of biopharmaceutical production and process development. Its offerings include cell line technologies, cell culture media, bioreactors, and various solutions for the separation, purification, and concentration of biological intermediates and finished products, as well as their storage and transportation. Headquartered in Aubagne, France, Sartorius Stedim Biotech is a subsidiary of Sartorius AG, which holds a significant majority of its share capital and voting rights. The company is publicly traded on the Euronext stock exchange in Paris.

Summarized from source with an LLMView SourceSector: Healthcare

Sales

Sales revenue including tariff compensation: €1,527m, up 6.4% in constant currencies (reported +2.5%). Operational sales revenue excluding tariff compensation grew 8.0% in constant currencies.

Profitability

Underlying EBITDA €479m, underlying EBITDA margin 31.4% (up 0.4 percentage points vs prior year). Management cites positive volume effects and economies of scale offsetting mix effects.

Net profit & earnings per share

Net profit €181m (up 17.6% vs PY €154m). Underlying net profit €235m (up 3.1% vs PY €228m). Underlying EPS €2.42 (PY €2.34); reported EPS €1.86 (PY €1.58).

Regional performance

EMEA: €672m, +7.7% cc. Americas: €512m (impacted by tariff compensation; excl. compensation +5.4% cc, incl. compensation +0.8% cc). Asia/Pacific: €342m, +12.5% cc, supported by China recovery.

Tariff refunds & customer compensation

At end of Q2 the company received U.S. tariff refunds related to levies invalidated by the U.S. Supreme Court; Sartorius Stedim Biotech intends to compensate customers for prior surcharges, with the related amounts recognized as reductions in cost of sales and sales revenue—this materially influenced the reported growth rates.

Guidance

Full‑year 2026 guidance confirmed: sales growth in constant currencies expected around 6–10% (operational sales growth broadly around the midpoint). Underlying EBITDA margin projected to increase to slightly above 31%. Customer compensation could reduce revenue by up to €35m versus initial assumptions and put growth in the lower half of the range.

Balance sheet & leverage

Equity €4,247m (equity ratio 53.6%). Gross debt €2,403m; net debt €2,199m. Net debt / underlying EBITDA 2.36 (down from 2.38 at year‑end 2025).

CapEx & employees

Investments €142m in H1 (capex/sales 9.3%, PY 9.5% for H1). Management expects full‑year capex ratio similar to prior year (PY 13.3%). Employees 10,477 at June 30, 2026 (up from 10,265).

Product launches

New introductions include the Ambr 250 HT Cell Therapies Vessel for scalable cell‑therapy process development and Pionic platform expansions (Quad and Cross modules) for intensified downstream processing.

Summarized from source with an LLMView Source

Key figures

7.77%1Y

-9.09%3Y

-52.1%5Y

Performance

40.4%1Y

44.1%3Y

44.5%5Y

Volatility